- Assisted dying
- Cancer
- Cardiovascular disease
- Dermatology
- Drug decriminalisation
- Emergency medicine
- Evidence-based medicine
- Gastroenterology
- Genetics
- Global health
- Hepatology
- Infectious disease
- Injury prevention
- Medical education
- Medical ethics
- Medical humanities
- Medical technology
- Medicines
- Mental health
- Neurology
- Occupational medicine
- Organisation of healthcare
- Paediatrics
- Pain
- Patients
- Primary care
- Public health
- Publishing
- Research process
- Respiratory medicine
- Sexual health
- Tobacco control
Organisation of healthcare
-
Dr James Cave
Drugs and Therapeutics Bulletin
Editor-in-Chief of the Drugs and Therapeutics Bulletin
-
Dr James Mountford
BMJ Leader
Editor-in-Chief of BMJ Leader
Dr James Cave
Drugs and Therapeutics Bulletin
Editor-in-Chief of the Drugs and Therapeutics Bulletin
Expertise: Medicines, primary care
Dr James Cave has been a GP for over 25 years. He currently works for Red Whale, providing courses for GPs that take the latest research and demonstrate how it might be used in practice. James was awarded an OBE for services to medicine in 2009.
Dr James Mountford
BMJ Leader
Editor-in-Chief of BMJ Leader
Expertise: clinical leadership, patient safety, quality improvement, co-production, unwarranted variation, value in healthcare
Dr James Mountford is Director of Quality at Royal Free London NHS Foundation Trust. He worked initially as an NHS doctor, then in consulting. From 2005-2007, he was a Commonwealth Fund/Health Foundation Harkness Fellow based in Massachusetts General Hospital, and at the Institute for Healthcare Improvement (IHI), both in Boston, USA. Before moving to the Royal Free, he was Director of Quality at UCLPartners, an academic health sciences partnership serving a population of 3 million in and around London. He sits on the board of AQuA, the improvement partnership based in north-west England. In March 2020 he was seconded to work as the Chief of Quality and Learning at the NHS Nightingale Hospital London, opened in response to the COVID-19 pandemic.